New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
11:15 EDTFLDM, GALT, BABY, LYGHigh option volume stocks: GALT AMLP LYG BABY FLDM
News For GALT;LYG;BABY;FLDM From The Last 14 Days
Check below for free stories on GALT;LYG;BABY;FLDM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
10:21 EDTGALTGalectin Therapeutics announces first patient dosed in GR-MD-02 trial
Galectin Therapeutics announced that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with NASH with advanced fibrosis has been successfully dosed with 4 mg/kg, which is double the dose given in cohort 1. Cohort 2, as with all phases of the clinical trial, was initiated in full compliance with the rules, regulations, and specific conditions set forth by the U.S. Food and Drug Administration for this Phase 1 clinical trial. The second cohort follows highly successful results from the first cohort showing that 2 mg/kg was safe and very well tolerated, and that GR-MD-02 treatment resulted in significant improvement in multiple biomarkers of fibrosis and liver inflammation in patients with NASH with advanced fibrosis. The remaining patients in cohort 2 are expected to be enrolled over the next few weeks and we anticipate reporting the results of cohort 2 around the end of July.
April 16, 2014
07:25 EDTLYGHitachi gathers $4.5B to finance Scotland-London express trains, Bloomberg says
Hitachi (HTHIY) has gathered $4.5B from an array of international institutions to fund its contract to construct 65 high-speed express trains to use on Britainís East Coast rail line between Scotland and London, according to Bloomberg, citing a company spokeswoman. Some of the lenders include the Bank of Tokyo-Mitsubishi, Japan Bank for International Cooperation, HSBC (HSBC), Lloyds Banking (LYG) and the European Investment Bank. Reference Link
April 14, 2014
07:04 EDTFLDMFluidigm upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.
April 9, 2014
08:24 EDTFLDMPiper Jaffray's medtech analysts hold an analyst/industry conference call
The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.
April 7, 2014
11:15 EDTGALT Options with decreasing implied volatility: MNKD GALT DLLR APOL
Subscribe for More Information
07:44 EDTFLDMMarketo to hold a summit
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use